WO1998007364A1 - Kontrollsystem für die überwachung der regelmässigen einnahme eines medikamentes - Google Patents
Kontrollsystem für die überwachung der regelmässigen einnahme eines medikamentes Download PDFInfo
- Publication number
- WO1998007364A1 WO1998007364A1 PCT/DE1997/001653 DE9701653W WO9807364A1 WO 1998007364 A1 WO1998007364 A1 WO 1998007364A1 DE 9701653 W DE9701653 W DE 9701653W WO 9807364 A1 WO9807364 A1 WO 9807364A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- control system
- detection device
- substance
- detection
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6802—Sensor mounted on worn items
- A61B5/681—Wristwatch-type devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to a control system for monitoring the regular intake of a drug in a patient and a pharmaceutical dosage form for such a control system.
- the invention proposes a control system which, as coordinated system components, comprises a dosage form of the medicament and a detection device for the non-invasive detection of a substance contained in the dosage form (hereinafter "detection substance") in the patient's body.
- detection substance a substance contained in the dosage form
- the detection device is designed for the reagent-free direct measurement of a measured variable correlating with the presence of the detection substance in the patient's body.
- the detection substance can be formed by the medicament itself, ie the therapeutically active substance. This is however, limited to cases in which the active substance is non-invasively detectable. Almost all chemotherapeutic agents have characteristic IR bands that can be used for a determination. Examples include: antibiotics such as tetracyclines, nitrofurones and nalidixic acid, the tuberculosis agents rifampicin and isonicotinic acid hydrazide, the antimalarial agent chloroquine, but also anticoagulants such as maramar and cardiovascular agents such as nitroglycerin and digoxin, which enable non-invasive detection.
- antibiotics such as tetracyclines, nitrofurones and nalidixic acid
- the antimalarial agent chloroquine but also anticoagulants such as maramar and cardiovascular agents such as nitroglycerin and digoxin
- the typical IR bands are overlaid by the bands of the body's own substances.
- a preferred embodiment of the invention in which the non-invasively detectable substance contained in the dosage form is a non-toxic marking substance different from the medicament (active substance).
- the marking substance is specifically chosen so that it does not impair the pharmaceutical effectiveness of the active pharmaceutical ingredient on the one hand and also does not cause any negative effects in the patient's body (preferably it behaves inertly in the body) and on the other hand its presence in the patient's body is easily detectable. It is possible to optimize the labeling substance, particularly from the point of view of easy detection.
- a toxic activity which is harmful to the body can, if necessary, be eliminated by encapsulation or incorporation into a macromolecular protective molecule structure, in particular a protective molecule from the group of the Dendri ere or Fullvalene.
- a macromolecular protective molecule structure in particular a protective molecule from the group of the Dendri ere or Fullvalene.
- the invention is explained in more detail below with the use of a separate marking substance. However, this is not intended to limit the generality - for cases in which the active substance itself has the properties of a suitable detection substance.
- Very different physically measurable quantities can serve as a measurement quantity. Examples are the intensity, the frequency or the phase position of an electromagnetic radiation (in particular of light in the IR range or also in the visible range), the intensity, frequency or phase position of a sound signal or the intensity or polarity of a magnetic field. It is crucial that the measured variable is influenced in a measurable manner by the presence of the marker substance in the patient's body, so that a change in the concentration of the marker substance associated with the use of the medicament can be detected with the aid of the measured variable by the detection device. Such a measured variable is referred to below as "parameter” in accordance with a term commonly used in the English language (“quantifiable parameter").
- the detection device preferably has means for determining the change in the parameter over time.
- Such electronic means for differentiating or for forming difference quotients from a measurement signal are known.
- An increase or decrease in the parameter measurement signal is preferably used as an indication of the intake of the medicament, ie an output signal corresponding to the "detection" of the labeling substance is generated when the parameter rameter measurement signal with a minimum change rate predetermined as a limit value increases or decreases.
- the invention is suitable for a wide variety of pharmaceutical dosage forms. It is of particular importance for oral administration (tablets, capsules and the like), but it can also be used for other dosage forms, such as suppositories or injections, insofar as monitoring of the regular administration of the medication is necessary. Of course, the marking substance must be brought into a galenical form suitable for the respective dosage form.
- the invention can have different mechanisms of action, i.e. on the basis of very different interactions between the marking substance and the detection device. Some preferred examples are explained below.
- the marking substance has dye properties, preferably in the IR region of the light spectrum.
- a detection device tuned to this radiates light of the appropriate wavelength through the skin into the patient's body and measures the light emerging from the body after interaction with the constituents contained therein (and thus also with the marking substance).
- the system components are expediently coordinated with one another in such a way that a possible high intensity of the incident light lies in a spectral range in which the marking substance has an absorption maximum.
- This wavelength is preferably chosen so that it is outside the absorption maxima of optically absorbing substances contained in the patient's body (in particular in his skin) in high concentration Substances lie, especially outside the absorption bands of water and hemoglobin.
- the light is usually irradiated in several wavelengths and the spectral dependence of the measured parameter of the light is used to detect the substance sought.
- the spectral dependence of the measured parameter of the light is used to detect the substance sought.
- several wavelengths are used in order to detect the marking substance spectroscopically.
- a particularly suitable mechanism of action is based on the use of a fluorescent dye as a labeling substance, the detection device being designed for in vivo detection of the fluorescence. For this purpose, it radiates light, the wavelength of which corresponds to the absorption wavelength of the fluorescent dye, into the patient's body. Lasers are particularly suitable as the light source for this. The resulting fluorescence radiation is detected in a wavelength-selective manner. Fluorescent dyes are preferably used which emit in the long-wave range of visible light and in the near infrared. Wavelengths are particularly preferred. lengths between about 600 nm and about 800 nm. Despite the low intensity of the emitted fluorescent light, this action mechanism proves to be particularly suitable for the purposes of the invention, because the superimposition of the useful signal with interference signals is relatively small and therefore a good comparison with other methods Signal / noise ratio results.
- Suitable labeling substances can be, for example, molecules that have been developed as marker molecules for diagnostic purposes. Examples include:
- Fluorescent labeling substances in particular fluorescein and fluorescent metal complex compounds, as are mentioned in WO 96/03410.
- Absorption or fluorescent dyes for example according to EP-B-0567 622.
- ferromagnetic microparticles the magnetic effect of which can be detected through the skin, can also be used as the marking substance.
- Electromagnetic radiation with a wavelength outside the spectrum of light can also be used as a probe for detecting the presence of a labeling substance in the patient's body.
- substances with diode properties can in particular be used as the marking substance. Details of this are described in WO 92/15 013.
- the marking substance has a pn junction which causes a diode behavior, ie in the electric field the substance is conductive in one field direction, while it has a high resistance in the other field direction.
- Such semiconductor diodes can be manufactured in micro-miniaturized form so that they act as marking sub- are generally suitable in a medication.
- the detection is carried out by influencing a high-frequency signal, preferably in the MHz range, as explained in the aforementioned WO 92/15 013.
- Fig. 2 is a block diagram of a detection device and an external interrogation unit and
- Fig. 3 is a graphical representation of a spectrum in an embodiment of the invention.
- the control system consists of a pharmaceutical dosage form 1 (here a tablet) which contains a marking substance symbolically identified by an asterisk and a detection device 2 which, in the preferred embodiment shown, is designed as a wristwatch worn by the patient 3.
- a detection device which is usually in the form of a device worn on the body, fulfills its control function in an inconspicuous manner that is not burdensome for the patient.
- the control device should be so small and light that it can be carried easily.
- the essential components of the detection device 2 are shown in the form of a block diagram in FIG. It contains irradiation and detection means 4 and 5, for example in the form of light-emitting diodes and semiconductor light receivers.
- the signals of the detection means are transmitted through a measuring and evaluation circuit 6 (for example processed by means of one of the methods described in the cited publications) into data on the presence of the marking substance in the body of the patient 3.
- a time measuring device 9 is provided in order to query the measuring time and also to store it in the memory 8.
- the detection device can be constructed relatively simply because no absolute concentration has to be determined. It is sufficient to demonstrate the increase in the concentration of the labeling substance associated with the drug intake. This can be done in terms of measurement technology, for example by means of a threshold value or (preferably) by determining the change in the parameter over time (i.e. formation of the first derivative of the measurement signal). Complex calibration procedures are not necessary.
- the data stored in the memory 8 can be further processed in the usual manner by the microprocessor-controlled measuring and evaluation unit.
- this can contain a program by which control measurements are initiated at certain predetermined times (for example once a day) in order to check whether the Patient has taken the medication and therefore evidence of the medication is possible.
- the program can also provide that in the event of a negative result of the check, a warning signal is generated by which an acoustic signal generator 11 is activated in order to inform the patient of the medication being taken.
- This can be varied in different ways. For example, it can be provided to remind the patient of the medication in each case by a tone without prior checking and to check the ingestion within a defined period afterwards by detecting the marking substance with the aid of the detection device 2.
- the data on the detection of the marking substance and on the measuring times are transmitted from the detection device 2 to an external interrogation unit 12.
- This external interrogation unit can be with the patient himself or with the doctor.
- the same or different query units can also be available to the doctor and the patient.
- the detection device 2 and the interrogation unit 12 should be designed such that the patient cannot delete or manipulate the data on the detection of the marking substance.
- the data is transmitted wirelessly from the detection device 2 to the external interrogation unit 12, the detection device 2 having a transmitter 13 and the interrogation unit 12 having a receiver 14, and the transmission being carried out, for example, with infrared rays or with FM radio signals .
- a data interface for wired transmission can also be provided on the detection device 2, to which the external interrogation unit 12 is connected from time to time by means of a cable.
- the Fluorescence of this fluorescent dye was measured in vivo in the ears of the mice.
- the excitation was carried out using a helium-neon laser with a power of approximately 1.5 mW and a wavelength of 632.8 nm.
- the fluorescent radiation was recorded with a fiber optic on the ear of the mice and focused on the emission monochromator of a fluorescence spectrometer.
- the resulting spectrum normalized to the maximum value, is shown in FIG. 3, the intensity I (in each case based on the maximum value) being plotted against the wavelength in nm.
- the measurement curve 16 shows the result of the in vivo measurements on the ear (measurement points as triangles).
- the measurement curve 17 shows the results of an in vitro measurement of the spectrum of the dye, likewise normalized to the maximum value, using the same spectrometer. It can be seen that the in vivo measurement agrees very well with the in vitro measurement. From this it can be concluded that it is possible to reliably detect changes in the concentration of a physiologically harmless dye in vivo at a suitable wavelength (in particular in the range of the maximum of the emission spectrum) using relatively simple means.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Optics & Photonics (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- General Physics & Mathematics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10510244A JP2000516504A (ja) | 1996-08-16 | 1997-08-01 | 薬剤の規則的摂取の監視システム |
US09/147,601 US6081734A (en) | 1996-08-16 | 1997-08-01 | Monitoring system for the regular intake of a medicament |
EP97936601A EP0928155A1 (de) | 1996-08-16 | 1997-08-01 | Kontrollsystem für die überwachung der regelmässigen einnahme eines medikamentes |
DE19780856T DE19780856D2 (de) | 1996-08-16 | 1997-08-01 | Kontrollsystem für die Überwachung der regelmäßigen Einnahme eines Medikamentes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19633025 | 1996-08-16 | ||
DE19633025.4 | 1996-08-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998007364A1 true WO1998007364A1 (de) | 1998-02-26 |
Family
ID=7802787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1997/001653 WO1998007364A1 (de) | 1996-08-16 | 1997-08-01 | Kontrollsystem für die überwachung der regelmässigen einnahme eines medikamentes |
Country Status (5)
Country | Link |
---|---|
US (1) | US6081734A (de) |
EP (1) | EP0928155A1 (de) |
JP (1) | JP2000516504A (de) |
DE (1) | DE19780856D2 (de) |
WO (1) | WO1998007364A1 (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2327016A (en) * | 1997-05-08 | 1999-01-06 | Motorola Inc | Multimode communication device operable in independent communication systems |
WO2011026808A1 (en) | 2009-09-03 | 2011-03-10 | Evonik Röhm Gmbh | Oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles |
CN104838254A (zh) * | 2012-11-30 | 2015-08-12 | 锡克拜控股有限公司 | 材料的标记、被标记材料和验证方法或稀释的确定 |
DE102005056310B4 (de) * | 2005-11-25 | 2017-02-02 | Drägerwerk AG & Co. KGaA | Verfahren und Vorrichtung zur Überwachung von Infusionen |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6299374B1 (en) | 2000-03-09 | 2001-10-09 | David Naor | Instruments for producing edible colored indicia on food substrates and medicaments |
AU2005284908B2 (en) | 2004-09-13 | 2011-12-08 | Morningside Venture Investments Limited | Biosynchronous transdermal drug delivery |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US8912908B2 (en) | 2005-04-28 | 2014-12-16 | Proteus Digital Health, Inc. | Communication system with remote activation |
US8802183B2 (en) | 2005-04-28 | 2014-08-12 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
US8836513B2 (en) | 2006-04-28 | 2014-09-16 | Proteus Digital Health, Inc. | Communication system incorporated in an ingestible product |
US8730031B2 (en) | 2005-04-28 | 2014-05-20 | Proteus Digital Health, Inc. | Communication system using an implantable device |
US9198608B2 (en) | 2005-04-28 | 2015-12-01 | Proteus Digital Health, Inc. | Communication system incorporated in a container |
CN103259027A (zh) | 2005-04-28 | 2013-08-21 | 普罗透斯数字保健公司 | 药物信息*** |
US8547248B2 (en) | 2005-09-01 | 2013-10-01 | Proteus Digital Health, Inc. | Implantable zero-wire communications system |
KR101568660B1 (ko) | 2006-05-02 | 2015-11-12 | 프로테우스 디지털 헬스, 인코포레이티드 | 환자 주문형 치료법 |
CN100500092C (zh) * | 2006-06-16 | 2009-06-17 | 周常安 | 具有可变结构的血液生理信号检测装置 |
ATE535057T1 (de) | 2006-10-17 | 2011-12-15 | Proteus Biomedical Inc | Niederspannungsoszillator für medizinische einrichtungen |
KR101611240B1 (ko) | 2006-10-25 | 2016-04-11 | 프로테우스 디지털 헬스, 인코포레이티드 | 복용 가능한 제어된 활성화 식별자 |
WO2008063626A2 (en) | 2006-11-20 | 2008-05-29 | Proteus Biomedical, Inc. | Active signal processing personal health signal receivers |
WO2008095183A2 (en) | 2007-02-01 | 2008-08-07 | Proteus Biomedical, Inc. | Ingestible event marker systems |
JP5614991B2 (ja) | 2007-02-14 | 2014-10-29 | プロテウス デジタル ヘルス, インコーポレイテッド | 大表面積電極を有する体内型電源 |
US9270025B2 (en) | 2007-03-09 | 2016-02-23 | Proteus Digital Health, Inc. | In-body device having deployable antenna |
EP2124725A1 (de) | 2007-03-09 | 2009-12-02 | Proteus Biomedical, Inc. | Körperintegrierte vorrichtung mit multidirektionalem sender |
US8540632B2 (en) | 2007-05-24 | 2013-09-24 | Proteus Digital Health, Inc. | Low profile antenna for in body device |
ES2928197T3 (es) | 2007-09-25 | 2022-11-16 | Otsuka Pharma Co Ltd | Dispositivo intracorpóreo con amplificación de señal de dipolo virtual |
EP3235491B1 (de) | 2008-03-05 | 2020-11-04 | Proteus Digital Health, Inc. | Verzehrbare marker und system für multimodale kommunikationsereignisse |
SG195535A1 (en) | 2008-07-08 | 2013-12-30 | Proteus Digital Health Inc | Ingestible event marker data framework |
CN102176862B (zh) | 2008-08-13 | 2014-10-22 | 普罗透斯数字保健公司 | 可摄入电路 |
JP2010091318A (ja) * | 2008-10-06 | 2010-04-22 | Seiko Epson Corp | 生体内薬剤濃度分布測定装置およびこれに用いる波長可変フィルタ、生体内薬剤濃度分布測定方法 |
KR101192690B1 (ko) | 2008-11-13 | 2012-10-19 | 프로테우스 디지털 헬스, 인코포레이티드 | 섭취 가능한 치료 활성화 시스템, 치료 장치 및 방법 |
AU2009324536A1 (en) | 2008-12-11 | 2011-07-14 | Proteus Digital Health, Inc. | Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same |
US9439566B2 (en) | 2008-12-15 | 2016-09-13 | Proteus Digital Health, Inc. | Re-wearable wireless device |
TWI503101B (zh) | 2008-12-15 | 2015-10-11 | Proteus Digital Health Inc | 與身體有關的接收器及其方法 |
US9659423B2 (en) | 2008-12-15 | 2017-05-23 | Proteus Digital Health, Inc. | Personal authentication apparatus system and method |
CN102365084B (zh) | 2009-01-06 | 2014-04-30 | 普罗秋斯数字健康公司 | 药剂递送*** |
JP2012514799A (ja) | 2009-01-06 | 2012-06-28 | プロテウス バイオメディカル インコーポレイテッド | 摂取に関連するバイオフィードバックおよび個別薬物療法の方法およびシステム |
WO2010111403A2 (en) | 2009-03-25 | 2010-09-30 | Proteus Biomedical, Inc. | Probablistic pharmacokinetic and pharmacodynamic modeling |
SG175388A1 (en) | 2009-04-28 | 2011-12-29 | Proteus Biomedical Inc | Highly reliable ingestible event markers and methods for using the same |
EP2432458A4 (de) | 2009-05-12 | 2014-02-12 | Proteus Digital Health Inc | Einnehmbarer ereignismarker mit verzehrbarem bestandteil |
EP2467707A4 (de) | 2009-08-21 | 2014-12-17 | Proteus Digital Health Inc | Vorrichtung und verfahren zur messung biologischer parameter |
TWI517050B (zh) | 2009-11-04 | 2016-01-11 | 普羅托斯數位健康公司 | 供應鏈管理之系統 |
UA109424C2 (uk) | 2009-12-02 | 2015-08-25 | Фармацевтичний продукт, фармацевтична таблетка з електронним маркером і спосіб виготовлення фармацевтичної таблетки | |
WO2011094606A2 (en) | 2010-02-01 | 2011-08-04 | Proteus Biomedical, Inc. | Data gathering system |
JP6463599B2 (ja) | 2010-04-07 | 2019-02-06 | プロテウス デジタル ヘルス, インコーポレイテッド | 小型の摂取可能なデバイス |
TWI557672B (zh) | 2010-05-19 | 2016-11-11 | 波提亞斯數位康健公司 | 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置 |
JP2014504902A (ja) | 2010-11-22 | 2014-02-27 | プロテウス デジタル ヘルス, インコーポレイテッド | 医薬品を有する摂取可能なデバイス |
US9439599B2 (en) | 2011-03-11 | 2016-09-13 | Proteus Digital Health, Inc. | Wearable personal body associated device with various physical configurations |
US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
CA2842952C (en) | 2011-07-21 | 2019-01-08 | Proteus Digital Health, Inc. | Mobile communication device, system, and method |
US9235683B2 (en) | 2011-11-09 | 2016-01-12 | Proteus Digital Health, Inc. | Apparatus, system, and method for managing adherence to a regimen |
ES2967970T3 (es) | 2012-07-23 | 2024-05-06 | Otsuka Pharma Co Ltd | Técnicas para fabricar marcadores de eventos ingeribles que comprenden un componente ingerible |
MY168018A (en) | 2012-10-18 | 2018-10-11 | Proteus Biomedical Inc | Apparatus, system , and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
TWI659994B (zh) | 2013-01-29 | 2019-05-21 | 美商普羅托斯數位健康公司 | 高度可膨脹之聚合型薄膜及包含彼之組成物 |
JP6498177B2 (ja) | 2013-03-15 | 2019-04-10 | プロテウス デジタル ヘルス, インコーポレイテッド | 本人認証装置システムおよび方法 |
WO2014144738A1 (en) | 2013-03-15 | 2014-09-18 | Proteus Digital Health, Inc. | Metal detector apparatus, system, and method |
JP6511439B2 (ja) | 2013-06-04 | 2019-05-15 | プロテウス デジタル ヘルス, インコーポレイテッド | データ収集および転帰の査定のためのシステム、装置、および方法 |
US9796576B2 (en) | 2013-08-30 | 2017-10-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
EP3047618B1 (de) | 2013-09-20 | 2023-11-08 | Otsuka Pharmaceutical Co., Ltd. | Verfahren, vorrichtungen und systeme zum empfang und zur decodierung eines signals in der gegenwart von rauschen mit slices und verzerrung |
WO2015044722A1 (en) | 2013-09-24 | 2015-04-02 | Proteus Digital Health, Inc. | Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance |
US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
DE102013113234A1 (de) | 2013-11-29 | 2015-06-03 | Deutsche Telekom Ag | Medikamentenbox |
CA2974324A1 (en) | 2015-01-28 | 2016-08-04 | Zita S. Netzel | Drug delivery methods and systems |
US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
US11051543B2 (en) | 2015-07-21 | 2021-07-06 | Otsuka Pharmaceutical Co. Ltd. | Alginate on adhesive bilayer laminate film |
MX2019000888A (es) | 2016-07-22 | 2019-06-03 | Proteus Digital Health Inc | Percepcion y deteccion electromagnetica de marcadores de evento ingeribles. |
CN109963499B (zh) | 2016-10-26 | 2022-02-25 | 大冢制药株式会社 | 用于制造具有可吸收事件标记器的胶囊的方法 |
US11285306B2 (en) | 2017-01-06 | 2022-03-29 | Morningside Venture Investments Limited | Transdermal drug delivery devices and methods |
US10978203B2 (en) * | 2017-06-20 | 2021-04-13 | International Business Machines Corporation | Power-efficient health affliction classification |
AU2019279884A1 (en) | 2018-05-29 | 2020-12-10 | Morningside Venture Investments Limited | Drug delivery methods and systems |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4867557A (en) | 1987-04-09 | 1989-09-19 | Sumitomo Electric Industries, Ltd. | Reflection type oximeter for applying light pulses to a body tissue to measure oxygen saturation |
DE3935257A1 (de) * | 1989-10-23 | 1991-04-25 | Langhals Heinz | Mit antikoerpern verknuepfte liposomen als traeger fuer einen gezielten transport von wirkstoffen und reagenzien - fluoreszenzmarkierung der transportwege und des wirkorts |
US5028787A (en) | 1989-01-19 | 1991-07-02 | Futrex, Inc. | Non-invasive measurement of blood glucose |
US5057695A (en) | 1988-12-19 | 1991-10-15 | Otsuka Electronics Co., Ltd. | Method of and apparatus for measuring the inside information of substance with the use of light scattering |
WO1992015013A1 (en) | 1991-02-22 | 1992-09-03 | Pa Consulting Services Limited | Detection of species |
WO1992017108A1 (en) * | 1991-04-03 | 1992-10-15 | Cedars-Sinai Medical Center | Photosensitizer enhanced fluorescence based biopsy needle |
US5187672A (en) | 1989-02-06 | 1993-02-16 | Nim Incorporated | Phase modulation spectroscopic system |
WO1994000602A1 (en) * | 1992-06-29 | 1994-01-06 | Sensor Technologies, Inc. | Method and device for detecting and quantifying substances in body fluids |
US5285783A (en) | 1990-02-15 | 1994-02-15 | Hewlett-Packard Company | Sensor, apparatus and method for non-invasive measurement of oxygen saturation |
WO1995032416A1 (de) | 1994-05-19 | 1995-11-30 | Boehringer Mannheim Gmbh | Verfahren und vorrichtung zur bestimmung eines analyten in einer biologischen probe |
EP0689848A1 (de) * | 1994-06-27 | 1996-01-03 | Commissariat A L'energie Atomique | Pulverinhalation |
US5487384A (en) * | 1993-02-25 | 1996-01-30 | Blue Marble Research, Inc. | Kinematic assay of plasma glucose concentration without blood sampling |
WO1996003410A1 (de) | 1994-07-25 | 1996-02-08 | Boehringer Mannheim Gmbh | Hydrophile metallkomplexe |
WO1996003650A1 (de) | 1994-07-25 | 1996-02-08 | Boehringer Mannheim Gmbh | Oligomere trägermoleküle mit definiert eingebauten markierungsgruppen und haptenen |
EP0567622B1 (de) | 1991-11-18 | 1996-04-24 | Roche Diagnostics GmbH | Neue pentacyclische verbindungen und ihre verwendung als absorptions- oder fluoreszenzfarbstoffe |
GB2309166A (en) * | 1996-01-20 | 1997-07-23 | Cleansharp Ltd | Detecting mis-use of drugs |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2257356A1 (de) * | 1972-11-20 | 1974-05-30 | Wolfgang Dr Med Wagner | Verwendung von druck- und wellenuebertragungsvorrichtungen insbesondere piezoelektrischer art und formverbesserung bei einrichtungen zur kontrollierten arzneiverabreichung durch den mund (perorale medikationskontrolle) |
DE3940260A1 (de) * | 1989-03-04 | 1990-09-13 | Werner Weitschies | Verfahren zur bestimmung des aufenthaltsortes und der bewegung von objekten durch ihre markierung als magnetisches moment |
US5036861A (en) * | 1990-01-11 | 1991-08-06 | Sembrowich Walter L | Method and apparatus for non-invasively monitoring plasma glucose levels |
US5200891A (en) * | 1990-01-17 | 1993-04-06 | Bruce A. Kehr | Electronic medication dispensing method |
DE4417639A1 (de) * | 1994-05-19 | 1995-11-23 | Boehringer Mannheim Gmbh | Verfahren zur Bestimmung eines Analyten in einer biologischen Probe |
NZ291155A (en) * | 1994-07-25 | 1997-09-22 | Boehringer Mannheim Gmbh | Production of hapten labelled peptides and their use |
US5572996A (en) * | 1994-09-19 | 1996-11-12 | Pdt Systems, Inc. | In vivo pharmacokinetics of photosensitive drugs and method |
-
1997
- 1997-08-01 EP EP97936601A patent/EP0928155A1/de not_active Withdrawn
- 1997-08-01 JP JP10510244A patent/JP2000516504A/ja active Pending
- 1997-08-01 DE DE19780856T patent/DE19780856D2/de not_active Expired - Lifetime
- 1997-08-01 US US09/147,601 patent/US6081734A/en not_active Expired - Fee Related
- 1997-08-01 WO PCT/DE1997/001653 patent/WO1998007364A1/de not_active Application Discontinuation
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4867557A (en) | 1987-04-09 | 1989-09-19 | Sumitomo Electric Industries, Ltd. | Reflection type oximeter for applying light pulses to a body tissue to measure oxygen saturation |
US5057695A (en) | 1988-12-19 | 1991-10-15 | Otsuka Electronics Co., Ltd. | Method of and apparatus for measuring the inside information of substance with the use of light scattering |
US5028787A (en) | 1989-01-19 | 1991-07-02 | Futrex, Inc. | Non-invasive measurement of blood glucose |
US5187672A (en) | 1989-02-06 | 1993-02-16 | Nim Incorporated | Phase modulation spectroscopic system |
DE3935257A1 (de) * | 1989-10-23 | 1991-04-25 | Langhals Heinz | Mit antikoerpern verknuepfte liposomen als traeger fuer einen gezielten transport von wirkstoffen und reagenzien - fluoreszenzmarkierung der transportwege und des wirkorts |
US5285783A (en) | 1990-02-15 | 1994-02-15 | Hewlett-Packard Company | Sensor, apparatus and method for non-invasive measurement of oxygen saturation |
WO1992015013A1 (en) | 1991-02-22 | 1992-09-03 | Pa Consulting Services Limited | Detection of species |
WO1992017108A1 (en) * | 1991-04-03 | 1992-10-15 | Cedars-Sinai Medical Center | Photosensitizer enhanced fluorescence based biopsy needle |
EP0567622B1 (de) | 1991-11-18 | 1996-04-24 | Roche Diagnostics GmbH | Neue pentacyclische verbindungen und ihre verwendung als absorptions- oder fluoreszenzfarbstoffe |
WO1994000602A1 (en) * | 1992-06-29 | 1994-01-06 | Sensor Technologies, Inc. | Method and device for detecting and quantifying substances in body fluids |
US5487384A (en) * | 1993-02-25 | 1996-01-30 | Blue Marble Research, Inc. | Kinematic assay of plasma glucose concentration without blood sampling |
WO1995032416A1 (de) | 1994-05-19 | 1995-11-30 | Boehringer Mannheim Gmbh | Verfahren und vorrichtung zur bestimmung eines analyten in einer biologischen probe |
EP0689848A1 (de) * | 1994-06-27 | 1996-01-03 | Commissariat A L'energie Atomique | Pulverinhalation |
WO1996003410A1 (de) | 1994-07-25 | 1996-02-08 | Boehringer Mannheim Gmbh | Hydrophile metallkomplexe |
WO1996003650A1 (de) | 1994-07-25 | 1996-02-08 | Boehringer Mannheim Gmbh | Oligomere trägermoleküle mit definiert eingebauten markierungsgruppen und haptenen |
GB2309166A (en) * | 1996-01-20 | 1997-07-23 | Cleansharp Ltd | Detecting mis-use of drugs |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2327016A (en) * | 1997-05-08 | 1999-01-06 | Motorola Inc | Multimode communication device operable in independent communication systems |
US6138010A (en) * | 1997-05-08 | 2000-10-24 | Motorola, Inc. | Multimode communication device and method for operating a multimode communication device |
DE102005056310B4 (de) * | 2005-11-25 | 2017-02-02 | Drägerwerk AG & Co. KGaA | Verfahren und Vorrichtung zur Überwachung von Infusionen |
WO2011026808A1 (en) | 2009-09-03 | 2011-03-10 | Evonik Röhm Gmbh | Oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles |
CN104838254A (zh) * | 2012-11-30 | 2015-08-12 | 锡克拜控股有限公司 | 材料的标记、被标记材料和验证方法或稀释的确定 |
Also Published As
Publication number | Publication date |
---|---|
EP0928155A1 (de) | 1999-07-14 |
JP2000516504A (ja) | 2000-12-12 |
DE19780856D2 (de) | 1999-09-23 |
US6081734A (en) | 2000-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998007364A1 (de) | Kontrollsystem für die überwachung der regelmässigen einnahme eines medikamentes | |
DE10027100C2 (de) | Verfahren und Vorrichtung zum Nachweisen von Substanzen in Körperflüssigkeiten | |
DE69032535T2 (de) | Verfahren und Vorrichtung zur Bestimmung der Ähnlichkeit eines biologischen Analyts, ausgehend von einem aus bekannten biologischen Fluiden hergestellten Modell | |
DE10011284B4 (de) | Vorrichtung für eine In-vivo Messung der Konzentration eines Inhaltsstoffs einer Körperflüssigkeit | |
DE60023162T2 (de) | Stethoskop | |
DE19612425C2 (de) | Apparat zur Messung von Hämoglobinkonzentration | |
DE69712255T2 (de) | Verfahren und Vorrichtung zur Messung der Glukosekonzentration | |
EP0707826B1 (de) | Verfahren und Vorrichtung zur Analyse von Glukose in einer biologischen Matrix | |
EP0726729B1 (de) | Verfahren und vorrichtung zur analyse von glucose in einer biologischen matrix | |
DE3031249C2 (de) | Vorrichtung zum Entdecken von Karies und Anwendung dieser Vorrichtung | |
DE68923941T2 (de) | Verfahren und Gerät zur Messung der Eigenschaften einer Substanz mittels Lichtstreuung. | |
DE10213692B4 (de) | Verfahren zur Steuerung einer Vorrichtung und Vorrichtung zur Messung von Inhaltsstoffen im Blut | |
EP1518495B1 (de) | Verfahren und Gerät zur laufenden Überwachung der Konzentration eines Analyten | |
DE69430791T2 (de) | Lichtsensor mit mehreren Lichtquellen | |
DE69227545T2 (de) | Oximeter zur zuverlässigen klinischen Bestimmung der Blutsauerstoffsättigung in einem Fötus | |
EP0728440B1 (de) | Auswerteverfahren und Vorrichtung zur tiefenselektiven, nicht-invasiven Detektion von Muskelaktivitäten | |
DE69837425T2 (de) | Verfahren und Vorrichtung zur nichtinvasiven photoakustischen Messung von Blutglukose | |
DE69933717T2 (de) | Optischer Sensor zur in situ Messung von Analyten | |
DE102010014775A1 (de) | Vorrichtung und Verfahren zur Bestimmen eines biologischen, chemischen und/oder physikalischen Parameters in lebendem biologischem Gewebe | |
DD300132A5 (de) | Einrichtung und verfahren zum nachweisen und messen der konzentration von substanzen in einer probe durch optoakustische spektroskopie | |
DE602004001794T2 (de) | Verfahren und Vorrichtung zur in vitro oder in vivo Messung der Konzentration einer Substanz | |
WO2001028414A2 (de) | Vorrichtung zur noninvasiven bestimmung der konzentration von bestandteilen im blut | |
CH640350A5 (en) | Instrument for the quantitative determination of optically active substances | |
DE69122506T2 (de) | Nichtinvasiver medizinischer sensor | |
EP1273904A2 (de) | Verfahren und Vorrichtung zur Erfassung von Stoffen in vitalem Gewebe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): DE JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09147601 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 1998 510244 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997936601 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997936601 Country of ref document: EP |
|
REF | Corresponds to |
Ref document number: 19780856 Country of ref document: DE Date of ref document: 19990923 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 19780856 Country of ref document: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997936601 Country of ref document: EP |